Menovo(SH:603538) Zheng Quan Zhi Xing·2025-08-26 16:23Summary of Key Points Core Viewpoint Ningbo Meinuo Pharmaceutical Co., Ltd. has reported on the status of its fundraising activities, detailing the amount raised, its usage, and the management of the funds as of June 30, 2025. The report highlights the company's commitment to regulatory compliance and effective fund management. Fundraising Basic Situation - The company raised a total of RMB 512,697,629.67 through the issuance of 5.2 million convertible bonds, with all funds received by January 20, 2021 [1]. - As of June 30, 2025, the net amount of actual raised funds was RMB 512,697,629.67, with RMB 120,013,509.22 allocated to supplement working capital [1][2]. Fund Usage and Balance - The company has utilized RMB 262,892,455.63 for the high-end formulation project and has also engaged in cash management with idle funds, generating a total of RMB 390.4 million in returns from investments [1][2]. - The total amount of idle funds invested in cash management reached RMB 29 million, with RMB 17 million redeemed during the reporting period [2][3]. Fund Management Situation - The company has established a dedicated account storage system for the raised funds, ensuring compliance with relevant regulations [1][2]. - As of June 30, 2025, the balance in the dedicated accounts totaled RMB 20,183,440.32, with specific accounts allocated for different projects [1][2]. Semi-Annual Fund Usage - The company has not experienced any delays in the planned progress of its fundraising investment projects, and there have been no significant changes in the feasibility of the projects [2][3]. - The high-end formulation project is expected to be completed by July 2025, with ongoing evaluations and adjustments to project timelines as necessary [3][4]. Changes in Fund Investment Projects - The company has approved changes to the allocation of funds, redirecting RMB 13,834.70 million from the high-end formulation project to the 734-ton pharmaceutical raw material project [4][5]. - There have been no instances of transferring or replacing the investment projects with external parties [4][5]. Issues in Fund Usage and Disclosure - The company has reported no significant issues in the usage and disclosure of the raised funds, maintaining transparency and compliance with regulatory requirements [4][5].